We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CGI Receives Approval to Provide Oncology Testing for Patients in California
News

CGI Receives Approval to Provide Oncology Testing for Patients in California

CGI Receives Approval to Provide Oncology Testing for Patients in California
News

CGI Receives Approval to Provide Oncology Testing for Patients in California

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CGI Receives Approval to Provide Oncology Testing for Patients in California"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cancer Genetics, Inc has announced that its CLIA-certified, CAP-accredited reference laboratory has received licensure from the California Department of Health. The California Clinical Laboratory License will allow the company to provide its state-of-the art oncology testing services for patient samples from the state of California.

"Approval to provide our comprehensive oncology tests and services throughout California opens up the single largest US oncology diagnostics market to CGI, and will help accelerate our commercial growth. CGI is well positioned to continue to empower the personalization of treatment by providing our unique technologies and tests for a region that demands innovation and access to world-class medical technology," said Panna Sharma, CEO of Cancer Genetics. "Although cancer rates in the State of California are relatively stable, there is a tremendous need to improve the costs associated with patient management and therapeutic selection, and provide molecular insights that can enable earlier and more comprehensive diagnosis. We will work closely with our partners, and with our sales and commercial team, to add value for clinicians, cancer centers, and regional providers to enable better, more informed diagnosis and prognosis of cancer."

In 2014, more than 171,000 new cases of cancer were diagnosed in the State of California, representing more than 10 percent of the total cancer incidence in the United States. The company believes that its proprietary tests and complete programs for Non-Hodgkin's Lymphoma (NHL) and leukemia will be of particular benefit to California, where more than 6,800 new patients are diagnosed with NHL, and 4,300 additional patients are diagnosed with leukemia each year.

Advertisement